Researchers Trace Differing Pediatric Brain Tumors to Common Source
New research has uncovered a shared biological weakness running across three distinct pediatric brain cancers, a finding that opens a realistic path toward therapies capable of targeting all three at once. The discovery grew out of a deep dive into one of the rarest childhood tumors on record and ended up revealing far more than anyone initially set out to find.
Pineoblastoma originates in the pineal gland, a small structure at the brain’s core responsible for producing hormones, including melatonin. Cases are rare enough that most specialized pediatric oncology programs handle only a small number each year.
Pooling resources across three institutions, St. Jude Children’s Research Hospital, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, and Uppsala University, the research team gathered tumor material from 38 patients. Analyzing that collection at the level of individual cells produced the most detailed molecular portrait of pineoblastoma assembled to date.
Mapping the disease first required understanding what healthy development looks like. Starting with no existing reference, the team built a comprehensive cellular roadmap of normal pineal gland formation from the ground up.
Running tumor cell profiles against that roadmap consistently highlighted one early cell population as the closest biological match to the cancer, pinpointing where the disease likely takes hold during development.
Separate laboratory models, each engineered around a different mutation known to drive the disease, all produced tumors that replicated their corresponding human counterparts in molecular and structural terms.
Despite originating from different genetic triggers, all the tumor subtypes carried a striking common thread. The pineal gland naturally maintains a gene collection involved in detecting light and regulating biological rhythms. Those same genes appeared consistently overactive in pineoblastoma.
Paul Northcott, corresponding author of the study and director of the Center of Excellence in Neuro-Oncology Sciences at St. Jude, said the pattern raised the possibility that these tumors require that elevated gene activity to persist, functioning almost like a biological dependency.
The same overactive gene network surfaced in medulloblastoma and in retinoblastoma, cancers rooted in completely different anatomical locations. Researchers applied CRISPR editing to deactivate those genes in cell lines from all three cancer types.
Each cancer type failed to survive the intervention, confirming that all three share a genuine reliance on that gene network rather than simply expressing it coincidentally.
Northcott said the confirmation of a cross-tumor dependency creates tangible grounds for designing therapies aimed at that shared target. Three cancers, each arising in a different part of the brain or nervous system and driven by different mutations, may ultimately be vulnerable to the same intervention. Pinpointing that shared weakness was the first step to building a treatment based on the discovery.
As more insights are accumulated about the origins of malignancies in the brain, the future work of drug development companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) focused on bringing to market better therapies against brain cancer could become a tad easier.
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer
New research has uncovered a shared biological weakness running across three distinct pediatric brain cancers, a finding that opens a realistic path toward therapies capable of targeting all three at once. The discovery grew out of a deep dive into one of the rarest childhood tumors on record and ended up revealing far more than anyone initially set out to find.
Pineoblastoma originates in the pineal gland, a small structure at the brain’s core responsible for producing hormones, including melatonin. Cases are rare enough that most specialized pediatric oncology programs handle only a small number each year.
Pooling resources across three institutions, St. Jude Children’s Research Hospital, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, and Uppsala University, the research team gathered tumor material from 38 patients. Analyzing that collection at the level of individual cells produced the most detailed molecular portrait of pineoblastoma assembled to date.
Mapping the disease first required understanding what healthy development looks like. Starting with no existing reference, the team built a comprehensive cellular roadmap of normal pineal gland formation from the ground up.
Running tumor cell profiles against that roadmap consistently highlighted one early cell population as the closest biological match to the cancer, pinpointing where the disease likely takes hold during development.
Separate laboratory models, each engineered around a different mutation known to drive the disease, all produced tumors that replicated their corresponding human counterparts in molecular and structural terms.
Despite originating from different genetic triggers, all the tumor subtypes carried a striking common thread. The pineal gland naturally maintains a gene collection involved in detecting light and regulating biological rhythms. Those same genes appeared consistently overactive in pineoblastoma.
Paul Northcott, corresponding author of the study and director of the Center of Excellence in Neuro-Oncology Sciences at St. Jude, said the pattern raised the possibility that these tumors require that elevated gene activity to persist, functioning almost like a biological dependency.
The same overactive gene network surfaced in medulloblastoma and in retinoblastoma, cancers rooted in completely different anatomical locations. Researchers applied CRISPR editing to deactivate those genes in cell lines from all three cancer types.
Each cancer type failed to survive the intervention, confirming that all three share a genuine reliance on that gene network rather than simply expressing it coincidentally.
Northcott said the confirmation of a cross-tumor dependency creates tangible grounds for designing therapies aimed at that shared target. Three cancers, each arising in a different part of the brain or nervous system and driven by different mutations, may ultimately be vulnerable to the same intervention. Pinpointing that shared weakness was the first step to building a treatment based on the discovery.
As more insights are accumulated about the origins of malignancies in the brain, the future work of drug development companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) focused on bringing to market better therapies against brain cancer could become a tad easier.
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer
